

03/09/00

JC780 U.S. PTO  
09/522160

3-10-00

A

JC525 U.S. PTO  
09/522160  
03/09/00

Case Docket No.: PROSL-7

Assistant Commissioner For Patents  
Washington, D.C. 20231

Transmitted herewith for filing is the patent application of:

Inventor: Brian K. Estabrook et al.  
For: PORT DEVICE FOR SUBCUTANEOUS ACCESS TO THE VASCULAR SYSTEM  
OF A PATIENT.

Enclosed are:

- ☒ 18 sheets of drawings.
- ☐ An assignment of the invention to: \_\_\_\_\_
- ☒ A verified statement to establish small entity status.
- ☐ \_\_\_\_\_

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Small Entity		Large Entity	
			Rate	Fee	Rate	Fee
Basic Fee				\$345.00		\$0.00
Total Claims	30 - 20	10	x \$ 9.00	90.00	x \$18.00	0.00
Ind. Claims	9 - 3	6	x \$39.00	234.00	x \$ 78.00	0.00
Mult. Claims			+ \$130.00		+ \$260.00	
Total				\$669.00		

- ☐ Please charge my Deposit Account No. 16-0221 to cover the filing fee and assignment recording fee. A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of \$669.00 to cover the filing fee (and assignment recording fee) is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0221. A duplicate copy of this sheet is enclosed.
  - ☒ Any additional filing fees required under 37 CFR 1.16.
  - ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 16-0221. A duplicate copy of this sheet is enclosed.
  - ☒ Any patent application processing fees under 37 CFR 1.17.
  - ☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
  - ☒ Any filing fees under 37 CFR 1.16 for presentation of extra claims.

Respectfully submitted,

M. Pandiscio 3/9/00  
Pandiscio & Pandiscio  
470 Totten Pond Road  
Waltham, Massachusetts 02451-1914  
Tel. (781) 290-0060

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Brian K. Estabrook et al.  
Title: PORT DEVICE FOR SUBCUTANEOUS  
ACCESS TO THE VASCULAR SYSTEM  
OF A PATIENT  
Attorney's Docket No.: PROSL-7

Assistant Commissioner For Patents  
Washington, D.C. 20231

VERIFIED STATEMENT CLAIMING SMALL BUSINESS ENTITY STATUS

The undersigned, Robert J. Mercier, hereby declares that he is CEO and President of Biolink Corporation, a Massachusetts corporation having a principal place of business at Middleboro, Massachusetts, and is empowered to act on behalf of said corporation in this matter; that said corporation qualifies as a small business concern as defined in 13 C.F.R. 121.3-18 for purposes of paying reduced fees under Title 35, United States Code, Sections 41(a) and (b), in that the number of employees of said corporation, including those of its affiliates, does not exceed 500 persons; and that on information and belief, exclusive rights under contract have been conveyed to and remain in said corporation with regard to the invention described and claimed in the above-identified U.S. patent application


For purposes of this statement, the number of employees of said corporation is the average over the previous fiscal year of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and concerns are affiliates of each other when either directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18, United States Code, Section 1001, and that such willful false statements may jeopardize the validity of the above-identified application, any patent issuing thereon, or any patent to which this verified statement is directed.

03/08/00  
Date

MB/PROSL7.VS

Biolink Corporation

  
Robert J. Mercier  
CEO and President